Bronstein, Gewirtz & Grossman, LLC Encourages Telix Pharmaceuticals Limited (TLX) Investors to Inquire about Securities Investigation

NEW YORK, NY / ACCESS Newswire / July 25, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Telix Pharmaceuticals Limited ("Telix" or "the Company") (NASDAQ:TLX). Investors who purchased Telix securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/TLX.

Investigation Details

On July 22, 2025, Telix disclosed receipt of a subpoena from the U.S. Securities and Exchange Commission, "seeking various documents and information primarily relating to the Company’s disclosures regarding the development of the Company’s prostate cancer therapeutic candidates." On this news, Telix’s American Depositary Receipt ("ADR") price fell $1.70 per ADR, or 10.44%, to close at $14.58 per ADR on July 23, 2025.

What’s Next?

If you are aware of any facts relating to this investigation or purchased Telix securities, you can assist this investigation by visiting the firm’s site: bgandg.com/TLX. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660

There is No Cost to You

We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.

Why Bronstein, Gewirtz & Grossman

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.

Follow us for updates on LinkedIn, X, Facebook, or Instagram.

Attorney advertising. Prior results do not guarantee similar outcomes.

Contact

Bronstein, Gewirtz & Grossman, LLC

Peretz Bronstein or Nathan Miller

332-239-2660 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

View the original press release on ACCESS Newswire

comtex tracking

COMTEX_467552578/2457/2025-07-25T12:23:03

Scroll to Top